HEM Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HEM Pharma - overview
Established
2017
Location
Pohang-si, Gyeongsangbukdo, South Korea
Primary Industry
Biotechnology
About
Founded in 2017 and based in Pohang, South Korea, HEM Pharma operates as a pharmaceutical development and healthcare company that uses microbiomes to analyze and improve human health. In November 2023, HEM Pharma Inc. raised KRW 1 billion in venture funding from new investor Celltrion. As of November 2023, the company is being led by its CEO, Ji Joseph, and Wilhelm Holzapfel, CTO.
The firm’s customers include Amway, Phyto Genomics, Enfominance, Samyang, GDK Cosmetics, etc. The company specializes in the design and manufacture of novel drugs based on research involving live microorganisms. When administered properly, these microorganisms confer health benefits to the host. Additionally, the platform is actively involved in delivering personalized health analytics services, creating health-functional foods, and granting customers access to valuable research findings pertaining to both cellular bodies and bacteria.
Current Investors
WOORI Venture Partners, CJ Investment, Friend Investment Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.hempharma.bio
Company Stage
Series A
Total Amount Raised
Subscriber access only
HEM Pharma - timeline of key events
HEM Pharma - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|
| Revenue (USD) | 1,857,259,307 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (9,549,938,890) | - | - | - |
| Operating Income (USD) | (10,954,767,890) | - | - | - |
| Operating Margin | (589.8%) | - | - | - |
| % EBITDA Margin | (514.2%) | - | - | - |
| NET Income (USD) | (10,919,143,576) | - | - | - |
| % Net Margin | (587.9%) | - | - | - |
HEM Pharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | HEM Pharma | - |
Displaying 1 - 1 of 1
HEM Pharma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.